Ionis To Get Head Start On Arrowhead With Tryngolza Launch

 
• By Andrew McConaghie
  
Ionis HQ
Roche will lead the Phase III development of the therapy, based on Ionis' antisense drug platform. • Source: Ionis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip